ESC Heart Failure最新文献

{"title":"Health-related quality of life across heart failure categories: associations with clinical characteristics and outcomes.","authors":"Camilla Settergren, Lina Benson, Ulf Dahlström, Tonje Thorvaldsen, Gianluigi Savarese, Lars H Lund, Bahira Shahim","doi":"10.1002/ehf2.15206","DOIUrl":"https://doi.org/10.1002/ehf2.15206","url":null,"abstract":"<p><strong>Aims: </strong>The study aims to examine characteristics and outcomes associated with health-related quality of life (HRQoL) in patients with heart failure (HF) with preserved, mildly reduced and reduced ejection fraction (EF) (HFpEF, HFmrEF and HFrEF).</p><p><strong>Methods and results: </strong>Data on HRQoL were collected in the Swedish Heart Failure Registry (SwedeHF; 2000-2021) using the EuroQoL 5-dimensional visual analogue scale (EQ 5D-vas). Baseline EQ 5D-vas scores were categorized as 'best' (76-100), 'good' (51-75), 'bad' (26-50) and 'worst' (0-25). Independent associations between patients' characteristics and EQ 5D-vas, as well as between EQ 5D-vas and outcomes were assessed. Of 40 809 patients (median age 74 years; 32% female), 29% were in the 'best', 41% in the 'good', 25% in the 'bad' and 5% in the 'worst' EQ 5D-vas categories, similarly distributed across all EF categories. Higher New York Heart Association (NYHA) class was strongly associated with lower EQ 5D-vas regardless of EF categories, followed by chronic obstructive pulmonary disease, smoking, body mass index, higher heart rate, anaemia, previous stroke, ischaemic heart disease, use of diuretics and living alone, whereas higher income, male sex, outpatient status and higher systolic blood pressure were inversely associated with lower EQ 5D-vas categories. Patients in the 'worst' EQ 5D-vas category as compared with the 'best' had the highest risk of all-cause death [adjusted hazard ratios 1.97, 95% confidence interval (CI) 1.64-2.37 in HFrEF, 1.77, 95% CI 1.30-2.40 in HFmrEF and 1.43 95% CI 1.02-2.00 in HFpEF].</p><p><strong>Conclusions: </strong>Most patients were in the two highest EQ 5D-vas categories. Higher NYHA class had the strongest association with lower EQ 5D-vas categories, across all EF categories. Patients in the worst EQ 5D-vas category were at the highest risk of mortality.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease","authors":"Özant Helvacı,&nbsp;Ömer Faruk Akçay,&nbsp;Emre Yaşar,&nbsp;Ülver Derici,&nbsp;Galip Güz","doi":"10.1002/ehf2.15230","DOIUrl":"10.1002/ehf2.15230","url":null,"abstract":"&lt;p&gt;We read with great interest the study by Kocabaş and colleagues, which brings attention to the suboptimal use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in heart failure (HF), particularly in patients with chronic kidney disease (CKD), where these drugs should be regarded as cornerstone therapies.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The RED-HEART study involving 1923 patients highlights that SGLT2is are disproportionately prescribed to patients with more severe disease. This feature is evidenced by the higher proportion of New York Heart Association Class IV cases and the increased concomitant use of angiotensin receptor-neprilysin inhibitors (ARNis), mineralocorticoid receptor antagonists (MRAs), and diuretics. This prescribing pattern underscores a concerning trend: SGLT2is are often perceived as add-on therapies for advanced cases rather than essential treatments in HF management. As the authors note, clinical inertia likely contributes to this suboptimal integration of SGLT2is into standard care, limiting their potential to significantly improve outcomes.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;HF and CKD are intricately intertwined, as the two conditions frequently coexist and share overlapping risk factors, pathophysiological mechanisms, and therapeutic targets. This interconnectedness underscores the importance of therapies like SGLT2is, which provide both cardiovascular and renal benefits.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The findings of the RED-HEART study present an opportunity to explore these renal aspects in greater depth.&lt;/p&gt;&lt;p&gt;The study does not clarify key methodological details, such as which estimated glomerular filtration rate (eGFR) formula was used (e.g., Chronic Kidney Disease Epidemiology Collaboration and Modification of Diet in Renal Disease) or the specific cut-off values applied to define CKD. These details are crucial for interpreting the characteristics and outcomes of the CKD subgroup within this cohort.&lt;/p&gt;&lt;p&gt;Although GFR staging and albuminuria are central to CKD assessment, neither appears to have been explicitly reported.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Albuminuria, in particular, is a marker not only of CKD severity but also of significant prognostic value in HF.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Including these metrics would provide a more nuanced understanding of the interplay between HF and CKD in the study population.&lt;/p&gt;&lt;p&gt;The cohort's median eGFR around 70 mL/min suggests that patients with stage 3B and 4 (combined eGFR between 15 and 45 mL/min) were likely excluded. Furthermore, the CKD prevalence of 28% in the cohort is notably lower than the 40%–50% typically reported in HF trials.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; This discrepancy likely reflects differences between real-world data and clinical trial populations.&lt;/p&gt;&lt;p&gt;It is well-established that as CKD progresses, HF with preserved ejection fraction (HFpEF) becomes more prevalent compared to HF with reduced ejection fraction (HFrEF).&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; In practice, distinguish","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":"12 2","pages":"1490-1491"},"PeriodicalIF":3.2,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ehf2.15230","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of baseline eGFR and incident heart failure on patients receiving intensive blood pressure treatment.","authors":"Li Haonan, He Qiaorui, Zhu Wenqing, Zhang Yanjun, Pingcuo Wangjia, Yu Shikai, Deji Zhuoga, Zhang Yi, Zhao Yifan","doi":"10.1002/ehf2.15232","DOIUrl":"https://doi.org/10.1002/ehf2.15232","url":null,"abstract":"<p><strong>Aims: </strong>We aim to elucidate the association of baseline eGFR and incident heart failure on patients receiving intensive BP treatment.</p><p><strong>Methods and results: </strong>A post hoc analysis was conducted on the SPRINT database. Multivariab le Cox regression and interaction restricted cubic spline (RCS) analysis were performed to investigate the interaction between baseline eGFR and intensive BP control on heart failure prevention. The primary endpoint focused on incident heart failure. The study cohort comprised 8369 adults with a mean [SD] age of 68 [59-77] years, including 2940 women (35.1%). Over a median [IQR] follow-up period of 3.9 [2.0-5.0] years, 183 heart failure events were recorded. A significant interaction was observed between baseline eGFR and treatment groups in terms of heart failure prevention (Interaction P = 0.012). The risk of heart failure showed a sharp slope until eGFR = 75 mL/min/1.73 m² and then became flat by an interaction RCS. Intensive BP treatment did not exhibit a preventive effect on heart failure (HR (95% CI) = 1.03 (0.82-1.52)) when baseline eGFR was 75 mL/min/1.73 m² or lower. Conversely, when baseline eGFR was higher than 75 mL/min/1.73 m², a reduced risk of heart failure was observed (HR (95% CI) = 0.65 (0.41-0.98)). Intensive BP control did not increase the incident long-term dialysis regardless of baseline eGFR but was associated with a higher risk of eGFR reduction.</p><p><strong>Conclusions: </strong>Among nondiabetic hypertensive patients, baseline eGFR serves as a crucial indicator for assessing the risk reduction potential of intensive BP control in heart failure prevention, with 75 mL/min/1.73 m² appearing as a suitable cut-off value.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal profiling of M-TEER-related complications.","authors":"Jafer Haschemi, Hanna Schrameck, Jean Marc Haurand, Daniel Oehler, Maximilian Spieker, Fabian Voss, Malte Kelm, Amin Polzin, Patrick Horn","doi":"10.1002/ehf2.15220","DOIUrl":"https://doi.org/10.1002/ehf2.15220","url":null,"abstract":"<p><strong>Aims: </strong>Transcatheter edge-to-edge repair of the mitral valve (M-TEER) is known for its low complication rates. However, the optimal level and duration of post-procedural care remain unclear. This study aimed to identify the specific timeframe of post-procedural complications following M-TEER.</p><p><strong>Methods and results: </strong>We conducted a retrospective analysis of 865 patients who underwent M-TEER at the University Hospital Düsseldorf between August 2010 and August 2023. Our analysis focused on a comprehensive examination of all acute post-procedural complications (1-100 h), considering the time point of occurrence or diagnosis. The complication analysed included cardiogenic shock, pericardial tamponade, stroke, cardiac arrhythmias, bleeding, acute kidney injury, myocardial infarction, peripheral vascular ischaemia and in-hospital mortality.</p><p><strong>Results: </strong>The median age was 80 (74, 84) years, and the EuroScore II was high (6.5 [4.0, 12.0] %). Functional mitral regurgitation (MR) was more common than degenerative or mixed MR (69% vs. 20%. respectively; 11%). Technical success rate was 97.2%. Overall, acute post-procedural complications occurred in 87 patients (10.1%). Most complications (75.9%) occurred within the first 4 h post-procedure. 12.6% of the complications occurred during the period between 4 and 24 h post-procedure, and 11.5% of the complications happened between 24 and 100 h post-procedure. Life-threatening complications were observed only within the first 4 h post-procedure.</p><p><strong>Conclusions: </strong>The majority of post-procedural complications after M-TEER occur within the first 4 h, with pericardial tamponade and major bleeding occurring only during this period. These findings provide valuable insight for physicians in determining the optimal surveillance and monitoring duration after M-TEER within clinical settings.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac myosin binding protein C correlate with cardiac troponin I during an exercise training program in patients with HFrEF.","authors":"E Riveland, A Ushakova, T Valborgland, T Karlsen, H Dalen, E Prescott, T Omland, A Linke, M Halle, M Marber, Ø Ellingsen, A I Larsen","doi":"10.1002/ehf2.15222","DOIUrl":"https://doi.org/10.1002/ehf2.15222","url":null,"abstract":"<p><strong>Background: </strong>Cardiac myosin binding protein C (cMyC) is an emerging new biomarker of myocardial injury rising earlier and cleared faster than cardiac troponins. It has discriminatory power similar to high-sensitive troponins in diagnosing myocardial infarction in patients presenting with chest pain. It is also associated with outcome in patients with acute heart failure. It is currently unclear how it relates to cardiac troponins in patients with chronic heart failure undergoing exercise training.</p><p><strong>Methods and results: </strong>This is a post hoc analysis of symptomatic heart failure patients in the multicentre randomized SMARTEX trial. Patients were randomized to one of three arms: high-intensity interval training, moderate continuous training and recommendation of regular exercise serving as control group (CG) for 12 weeks. As the training load in the two intervention arms was similar, these patients were merged and constituted the intervention group (IG). Clinical data and measurements were obtained at baseline and at 12 weeks. In 205 patients, serum was available for cMyC testing and in 196 patients, serum was available for hs-cTni testing. Due to non-normal distribution, cMyC and hs-cTnI measurements were log-transformed. A Bland-Altman plot was employed to evaluate the agreement of cMyC with hs-cTnI measurements. Lastly, a linear regression model was applied. No significant differences were observed in the change of cMyC levels between the groups throughout the intervention period (∆ cMyC IG: -0.5 [IQR: -3.4; 2.1] vs. ∆ cMyC CG: -0.7 [IQR: -2.7; 2.6]). The change in log hs-cTnI was significantly correlated with the change in log cMyC during the 12-week intervention period, with a Pearson correlation coefficient of R = 0.52 (95% CI 0.37-0.66, P < 0.001). For every 10% increase in cMyC levels, hs-cTnI levels rose by approximately 5%.</p><p><strong>Conclusions: </strong>Changes in levels of the novel biomarker cMyC were significantly associated with hs-cTnI serum levels in patients with symptomatic chronic HFrEF during a structured 12-week exercise training programme. This may indicate that cMyC has a role as a future marker of subclinical myocardial damage.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age.","authors":"Roy Rasalam, Andrew Sindone, Gary Deed, Ralph G Audehm, John J Atherton","doi":"10.1002/ehf2.15205","DOIUrl":"https://doi.org/10.1002/ehf2.15205","url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) is defined by heart failure (HF) with a left ventricular ejection fraction (LVEF) of at least 50%. HFpEF has a complex and heterogeneous pathophysiology with multiple co-morbidities contributing to its presentation. Establishing the diagnosis of HFpEF can be challenging. Two algorithms, the 'Heavy, 2 or more Hypertensive drugs, atrial Fibrillation, Pulmonary hypertension, Elderly age >60, elevated Filling pressures' (H₂FPEF) and the 'Heart Failure Association Pre-test assessment, Echocardiography and natriuretic peptide, Functional testing, Final aetiology' (HFA-PEFF), can help to determine the likelihood of HFpEF in individuals with symptoms of HF. Phenotype clusters defined largely by the total number and types of co-morbidities may delineate groups of patients with HFpEF with different management needs. It is important to recognize alternative diagnoses or HFpEF mimics such as infiltrative cardiomyopathies, coronary artery disease, lung disease, anxiety, depression, anaemia, severe obesity, and physical deconditioning, among others. Treatment with sodium-glucose co-transporter 2 inhibitors (dapagliflozin and empagliflozin) is recommended for all patients with HFpEF unless contraindicated. Future research should consider alternative approaches to guide the initial diagnosis and treatment of HFpEF, including phenotype clustering models and artificial intelligence, and consider whether LVEF is the most useful distinguishing feature for categorizing HF. Ongoing clinical trials are evaluating novel pharmacological and device-based approaches to address the pathophysiological consequences of HFpEF.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the Tpeak-Tend interval on admission and coronary microvascular dysfunction in Takotsubo syndrome.","authors":"Kyohei Onishi, Masafumi Ueno, Nobuhiro Yamada, Kazuyoshi Kakehi, Kosuke Fujita, Koichiro Matsumura, Gaku Nakazawa","doi":"10.1002/ehf2.15214","DOIUrl":"https://doi.org/10.1002/ehf2.15214","url":null,"abstract":"<p><strong>Aims: </strong>The Tpeak-Tend interval on electrocardiogram may be a predictor of worse outcomes in Takotsubo syndrome (TTS), but the mechanisms have not been fully determined. This study aimed to investigate the relationships between the corrected Tpeak-Tend (cTp-e) interval and coronary microvascular-dysfunction (CMD) assessed by the angiography-derived index of microvascular resistance (Angio-IMR) and the in-hospital prognosis in patients with TTS.</p><p><strong>Methods and results: </strong>We retrospectively evaluated 111 consecutive patients admitted for TTS who underwent coronary angiography at Kindai University Hospital from October 2009 to July 2023. The Tpeak-Tend interval was defined as the time interval between the peak and the end of the T wave in electrocardiogram lead V5 on admission. Angio-IMR was assessed from aortic pressure, quantitative flow ratio (QFR), vessel length and hyperemic velocity using the formula described in validation studies. QFR, vessel length and hyperemic velocity was derived from coronary angiography and QAngio XA 3D software package. The degree of CMD was assessed by the maximum Angio-IMR value in each of the three coronary arteries. The primary endpoint was the relationship between the grade of a prolonged cTp-e interval on admission and Angio-IMR. The secondary endpoint was the relationship between the grade of a prolonged cTp-e interval on admission and in-hospital adverse cardiovascular events (composite of acute heart failure, cardiogenic shock, life-threatening arrhythmia, thrombotic events, stroke and all-cause death). The median age was 77.5 [71.0-83.0] years, and most patients were women (82.0%). The median cTp-e interval was 114.5 [91.2-147.0] ms. The patients were categorized according to the tertiles of the cTp-e interval (T1: 52.4-96.9 ms; T2: 100.1-129.1 ms; T3: 131.7-309.8 ms). There was a stepwise increment in the values of maximum Angio-IMR in each of the three coronary arteries in tertiles of the cTp-e interval (T1 vs. T2 vs. T3: 16.1 [14.7-19.3] vs. 21.8 [16.0-31.1] vs. 29.0 [27.2-31.9], P < 0.001). In-hospital adverse cardiovascular events occurred in 53 of 111 patients (47.7%). There was a stepwise increment in the incidence of in-hospital adverse cardiovascular events in tertiles of the cTp-e interval (T1 vs. T2 vs. T3: 27.1% vs. 54.1% vs. 62.2%, P = 0.007). The multivariable analysis showed that prolonged cTp-e interval (OR: 1.30; 95% CI: 1.12-1.56; P < 0.001) was independent predictors of in-hospital adverse cardiovascular events.</p><p><strong>Conclusions: </strong>The Tpeak-Tend interval on admission reflected CMD and predicts in-hospital adverse cardiovascular events in patients with TTS.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frailty determinants in heart failure: Inflammatory markers, cognitive impairment and psychosocial interaction.","authors":"Marta Wleklik, Christopher S Lee, Łukasz Lewandowski, Michał Czapla, Maria Jędrzejczyk, Heba Aldossary, Izabella Uchmanowicz","doi":"10.1002/ehf2.15208","DOIUrl":"https://doi.org/10.1002/ehf2.15208","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to identify factors associated with frailty in heart failure (HF) patients, focusing on demographic, biochemical and health-related variables. It also explored the correlation between frailty and comorbidities such as malnutrition, cognitive impairment and depression, assessing how these factors interact to influence frailty risk.</p><p><strong>Methods: </strong>A total of 250 HF patients (mean age 73.5 ± 7.2 years; 45.6% female) hospitalized for acute decompensated HF were included. Frailty was assessed using Fried phenotype criteria. Cognitive function, depression and nutritional status were evaluated using validated instruments [Mini-Mental State Examination (MMSE), Patient Health Questionnaire-9 (PHQ-9) and Mini Nutritional Assessment (MNA)]. Biochemical markers included C-reactive protein (CRP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), haemoglobin, estimated glomerular filtration rate (eGFR) and systolic blood pressure (SBP). Statistical analyses, including logistic regression, were performed to assess associations and odds ratios (ORs) for frailty, adjusted for inflammation and HF type.</p><p><strong>Results: </strong>Frailty was present in 60.4% of patients. Frail individuals exhibited significantly higher CRP (median 4.60 vs. 2.54 mg/L, P < 0.001) and NT-proBNP (median 2558.8 vs. 1102.6 pg/mL, P = 0.001) and lower haemoglobin (13.7 vs. 14.3 g/dL, P = 0.012), eGFR (62 vs. 71 mL/min/1.73 m², P = 0.025) and SBP (130 vs. 134 mmHg, P = 0.026). Each 10% increase in CRP was associated with a 5.5% increase in frailty odds (P < 0.001). Frailty was linked to cognitive impairment (OR 2.1, P = 0.018), malnutrition (OR 3.0, P < 0.001) and depression (OR 3.1, P < 0.001), while high adherence to treatment reduced frailty risk by 78.9% (P = 0.027). Interactions were observed between cognitive impairment and body mass index (BMI) (P = 0.020), where higher BMI mitigated the frailty odds difference between cognitively impaired and unimpaired patients. Depression's association with frailty odds varied by adherence levels (P = 0.034) and central obesity (P = 0.047), with the absence of depression offering protection against frailty in patients with central obesity. These interactions remained significant after adjustment for HF type and left ventricular ejection fraction (LVEF) and were consistent across stratifications by these factors.</p><p><strong>Conclusions: </strong>Frailty in HF is influenced by inflammatory markers, cognitive impairment and psychosocial factors. Elevated CRP and NT-proBNP were strong predictors of frailty. Cognitive impairment and depression were key modifiable factors, interacting with BMI, adherence and obesity. Targeting these factors with early interventions could mitigate frailty risk, improving outcomes and quality of life in HF patients.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization","authors":"Tauben Averbuch,&nbsp;Ali Zafari,&nbsp;Shofiqul Islam,&nbsp;Shun Fu Lee,&nbsp;Rajiv Sankaranarayanan,&nbsp;Stephen J Greene,&nbsp;Mamas A Mamas,&nbsp;Ambarish Pandey,&nbsp;Harriette GC Van Spall","doi":"10.1002/ehf2.15129","DOIUrl":"10.1002/ehf2.15129","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aims&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Risk prediction indices used in worsening heart failure (HF) vary in complexity, performance, and the type of datasets in which they were validated. We compared the performance of seven risk prediction indices in a contemporary cohort of patients hospitalized for HF.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods and results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We assessed the performance of the Length of stay and number of Emergency department visits in the prior 6 months (LE), Length of stay, number of Emergency department visits in the prior 6 months, and admission N-Terminal prohormone of brain natriuretic peptide (NT-proBNP (LENT), Length of stay, Acuity, Charlson co-morbidity index, and number of Emergency department visits in the prior 6 months (LACE), Get With The Guidelines Heart Failure (GWTG), Readmission Risk Score (RRS), Enhanced Feedback for Effective Cardiac Treatment model (EFFECT), and Acute Decompensated Heart Failure National Registry (ADHERE) risk indices among consecutive patients hospitalized for HF and discharged alive from January 2017 to December 2019 in a network of hospitals in England. The primary composite outcome was 30-day all-cause mortality or readmission. We assessed model discrimination and overall accuracy using the C-statistic (higher values, better) and Brier score (lower values, better), respectively. Among 1206 patients in the cohort, 45.0% were female, mean (SD) age was 76.6 (11.7) years, and mean (SD) left ventricular ejection fraction was 43.0% (11.6). At 30 days, 236 (19.6%) patients were readmitted and 28 (2.3%) patients died, with 264 (21.9%) patients experiencing either readmission or death. The LENT index offered the combination of greatest risk discrimination and accuracy for the primary composite outcome (C-statistic: 0.97; 95% CI 0.96, 0.98; 0.29; Brier score: 0.05). The LE (C-statistic: 0.95; 95% CI 0.93, 0.96; Brier score: 0.06) and LACE (C-statistic: 0.90; 95% CI 0.88, 0.92; Brier score 0.09) indices had high discrimination and accuracy. Discrimination and accuracy were modest with the RRS (C-statistic: 0.65; 95% CI 0.61, 0.69; Brier score: 0.16) and EFFECT (C-statistic: 0.64; 95% CI 0.60, 0.67; Brier score: 0.16) score; and poor with the GWTG-HF (C-statistic: 0.62; 95% CI 0.58, 0.66; Brier score: 0.17) and ADHERE (C-statistic: 0.54; 95% CI 0.50, 0.57; Brier score: 0.17) scores.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In a study that compared the performance of seven risk prediction indices in a contemporary cohort of patients hospitalized for HF, the simple LENT index offered the greatest combination of discrimination and accuracy for the primary composite outcome of 30-day all-cause mort","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":"12 2","pages":"1227-1236"},"PeriodicalIF":3.2,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ehf2.15129","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to ‘Incidence and predictors of heart failure with improved ejection fraction category in a HFrEF patient population’","authors":"","doi":"10.1002/ehf2.15209","DOIUrl":"10.1002/ehf2.15209","url":null,"abstract":"<p>\u0000 <span>Solymossi, B.</span>, <span>Muk, B.</span>, <span>Sepp, R.</span>, <span>Habon, T.</span>, <span>Borbély, A.</span>, <span>Heltai, K.</span>, <span>Majoros, Z.</span>, <span>Járai, Z.</span>, <span>Vágány, D.</span>, <span>Szatmári, Á.</span>, <span>Sziliczei, E.</span>, <span>Bánfi-Bacsárdi, F.</span>, and <span>Nyolczas, N.</span> (<span>2024</span>) <span>Incidence and predictors of heart failure with improved ejection fraction category in a HFrEF patient population</span>. <i>ESC Heart Failure</i>, <span>11</span>: <span>783</span>–<span>794</span>. 10.1002/ehf2.14619.</p><p>The following affiliation of the first and last authors was not included in the published version: Károly Rácz Doctoral School of Clinical Medicine, Semmelweis University, Budapest, Hungary</p><p>The author links and affiliations should have read:</p><p>Balázs Solymossi^1,2, Balázs Muk¹, Róbert Sepp³, Tamás Habon⁴, Attila Borbély⁵, Krisztina Heltai⁶, Zsuzsanna Majoros⁷, Zoltán Járai⁸, Dénes Vágány⁷, Ákos Szatmári⁹, Erzsébet Sziliczei¹⁰, Fanni Bánfi-Bacsárdi¹, Noémi Nyolczas^1,2</p><p>¹Gottsegen National Cardiovascular Center, Budapest, Hungary</p><p>²Károly Rácz Doctoral School of Clinical Medicine, Semmelweis University, Budapest, Hungary</p><p>³Division of Non-Invasive Cardiology, Department of Internal Medicine, University of Szeged, Szeged, Hungary</p><p>⁴Division of Cardiology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary</p><p>⁵Division of Cardiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary</p><p>⁶Heart and Vascular Center, Semmelweis University, Budapest, Hungary</p><p>⁷Department of Cardiology, Central Hospital of Northern Pest-Military Hospital, Budapest, Hungary</p><p>⁸South-Buda Center Hospital, St Imre University Teaching Hospital, Budapest, Hungary</p><p>⁹Cardiology Outpatient Clinic, Institute for Aviation Medicine, Military Fitness, and Medicine, Hungarian Defence Forces, Kecskemét, Hungary</p><p>¹⁰Fejér County Szent György University Teaching Hospital, Székesfehérvár, Hungary</p><p>We apologize for this error.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":"12 2","pages":"1523"},"PeriodicalIF":3.2,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ehf2.15209","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}